AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

AJ201 (rosolutamide) is described as the only known investigational therapy for spinal and bulbar muscular atrophy (SBMA) in Phase 3 development worldwide. The oral small molecule is designed to address multiple disease mechanisms; the excerpt reports no clinical results or other outcome data.